In a recent analysis of 7,200 cancer research abstracts from the American Association for Cancer Research's (AACR) annual gathering, several significant trends emerged.

April 15, 2024 —An innovative gene therapy named AVB-101 is currently under investigation to treat frontotemporal dementia (FTD) caused by progranulin (GRN) gene mutations.

April 15, 2024 —NiKang Therapeutics Inc. recently announced the commencement of a phase 1/1b clinical trial involving their novel drug candidate NKT3447.

April 15, 2024 —Neumora Therapeutics, a biopharmaceutical firm listed on Nasdaq as NMRA, has encountered a setback in its clinical trials.

April 15, 2024 —Walden Biosciences, a private clinical development company, has reported positive results from its Phase 1+ study of WAL0921.

April 15, 2024 —A recent publication in Nature Medicine has highlighted the advancements in vaccine design, specifically focusing on Gritstone bio's neoantigen platform, SLATE.

April 15, 2024 —In a recent study, patients with Angelman syndrome demonstrated significant improvements in various areas after treatment with GTX-102.

TransCode Therapeutics, an RNA oncology company, has received approval from the U.S. Food and Drug Administration (FDA) to commence a Phase 1/2 clinical trial for its lead therapeutic candidate, TTX-MC138.

April 15, 2024 — ORIC Pharmaceuticals, a clinical-stage oncology company, has completed the dose escalation phase of its Phase 1b trial for ORIC-114.

Senti Bio reports initial dosing in a Phase 1 trial for SENTI-202, targeting recurrent or treatment-resistant blood cancers like Acute Myeloid Leukemia.

May 15th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Novo Nordisk A/S reports that in the Frontier 2 study, their once-weekly and once-monthly Mim8 treatments significantly outperformed standard and prior prophylaxis treatments in reducing bleeding episodes in individuals with haemophilia A.